FGFR2 Amplification in Colorectal Adenocarcinoma...
Cold Spring Harbor Laboratory Press; August 29, 2017 doi:10.1101/mcs.a001495
Jamal H Carter MD, Catherine E Cottrell PhD, Samantha N McNulty PhD, Katinka A Vigh-Conrad PhD, Stephen Lamp, Jonathan W Heusel MD, Eric J Duncavage MD
FGFR2 is recurrently amplified in 5% of gastric cancers and 1-4% of breast cancers; however, this molecular alteration has never been reported in a primary colorectal cancer specimen. Preclinical studies indicate that several FGFR tyrosine-kinase inhibitors (TKI), such as AZD4547, have in vitro activity against the FGFR2-amplified colorectal cell line, NCI-H716. The efficacy of these inhibitors is currently under investigation in clinical trials for breast and gastric cancer. Thus, better characterizing colorectal tumors for FGFR2 amplification could identify a subset of patients who may benefit from FGFR TKI therapies. Here, we describe a novel FGFR2 amplification identified by clinical next-generation sequencing (NGS) in a primary colorectal cancer. Further characterization of the tumor by immunohistochemistry showed neuroendocrine differentiation, similar to the reported properties of the NCI-H716 cell line. These findings demonstrate that the spectrum of potentially clinically actionable mutations detected by targeted clinical sequencing panels is not just limited to single nucleotide polymorphisms and insertions/deletions, but also copy number alterations.
To Access Article, Click Here
Have Any Questions Regarding This Article? Contact Our Team Today